Quintrio
Home

SERVICES-MISC HEALTH & ALLIED SERVICES, NEC

Viemed Healthcare, Inc. Common Shares

VMD

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.

Last trade $9.11
Day change -$0.045 (-0.49%)
Day range $8.89 – $9.26
Volume 75,747
Market cap $347M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$346.72M
Price / earnings
22.19×
Price / book
2.31×
Price / sales
1.12×
EV / sales
1.1×
EV / EBITDA
6.11×

Profitability

Earnings per share
$0.41
Return on assets
7.52%
Return on equity
10.41%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.03×
Current ratio
1.25×
Quick ratio
1.16×
Cash ratio
0.2×

Cash flow

Price / cash flow
6.43×
Price / free cash flow
16.22×
Free cash flow
$21.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$80.67M$78.1M$75.41M$76.18M$71.91M$63.06M$59.13M$60.7M
Cost of revenue$34.48M$33.05M$32.59M$32.08M$30.57M$26.33M$25.85M$24.56M
Gross profit$46.19M$45.05M$42.83M$44.1M$41.35M$36.73M$33.28M$36.14M
Selling, general and administrative$35.51M$39.16M$37.24M$34.52M$31.92M$31.14M$30.74M$29.73M
Research and development$501K$504K$579K$598K$775K$847K$797K$803K
Total operating expenses$38.88M$40.06M$38.21M$35.5M$35.27M$32.34M$31.88M$30.88M
Operating income$7.32M$4.99M$4.62M$8.6M$6.07M$4.39M$1.4M$5.26M
Interest expense-$177K-$248K-$305K$0-$507K-$132K-$179K$0
Income before taxes$6.79M$4.05M$3.99M$8.01M$5.14M$4.96M$3.66M$6.31M
Income taxes$2.05M$1.15M$1.28M$2.19M$1.54M$1.71M$952K$1.88M
Net income$4.74M$2.9M$2.71M$5.82M$3.6M$3.25M$2.71M$4.42M
Net income attributable to common shareholders$4.64M$2.76M$2.58M$5.64M$3.51M$3.16M$2.63M$4.32M
EBITDA$15.03M$12.51M$12.24M$16.17M$13.61M$11.28M$8.01M$11.63M
Basic earnings per share$0.12$0.07$0.07$0.15$0.09$0.08$0.07$0.11
Diluted earnings per share$0.11$0.07$0.06$0.14$0.09$0.08$0.06$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates

CeriBell, Inc. (CBLL) reported a quarterly loss of $0.48 per share, beating consensus estimates of $0.50 loss, with revenues of $29.34 million exceeding expectations by 0.70%. However, losses widened year-over-year from $0.37 to $0.48 per share. The stock has gained 22.9% year-to-date but carries a Zacks Rank #3 (Hold) rating, with the Medical-Products industry ranking in the bottom 35% of sectors.

Zacks Investment Research

Boston Scientific (BSX) Q3 Earnings Match Estimates

Boston Scientific reported Q3 2026 earnings of $0.73 per share, matching consensus estimates, with revenues of $5.14 billion slightly exceeding expectations. However, the stock has underperformed significantly, down 52.7% year-to-date versus the S&P 500's 12.8% gain. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, and its industry (Medical - Products) ranks in the bottom 34% of sectors.

Zacks Investment Research

Do Options Traders Know Something About Viemed Stock We Don't?

Viemed Healthcare (VMD) is drawing attention from options traders due to high implied volatility in its November 2026 $5.00 call options, suggesting market expectations for significant price movement. However, the company maintains a Zacks Rank #3 (Hold) rating, and analyst consensus estimates for the upcoming quarter have declined slightly from 13 cents to 12 cents per share over the last 60 days. The elevated implied volatility may present opportunities for premium-selling strategies rather than directional bets.

GlobeNewswire Inc.

Viemed Healthcare Announces Record 2024 Financial Results

Viemed Healthcare, a leading provider of respiratory care and home medical equipment services, reported record financial results for the fourth quarter and full year 2024, with strong growth in revenue, net income, and patient counts. The company also provided guidance for 2025, expecting continued growth in revenue and adjusted EBITDA.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.